JP2005516035A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516035A5
JP2005516035A5 JP2003561625A JP2003561625A JP2005516035A5 JP 2005516035 A5 JP2005516035 A5 JP 2005516035A5 JP 2003561625 A JP2003561625 A JP 2003561625A JP 2003561625 A JP2003561625 A JP 2003561625A JP 2005516035 A5 JP2005516035 A5 JP 2005516035A5
Authority
JP
Japan
Prior art keywords
melagatran
medicament
kit
pharmaceutically acceptable
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516035A (ja
Filing date
Publication date
Priority claimed from SE0200198A external-priority patent/SE0200198D0/xx
Application filed filed Critical
Publication of JP2005516035A publication Critical patent/JP2005516035A/ja
Publication of JP2005516035A5 publication Critical patent/JP2005516035A5/ja
Pending legal-status Critical Current

Links

JP2003561625A 2002-01-23 2003-01-21 I型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用 Pending JP2005516035A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (2)

Publication Number Publication Date
JP2005516035A JP2005516035A (ja) 2005-06-02
JP2005516035A5 true JP2005516035A5 (cg-RX-API-DMAC7.html) 2006-03-09

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561625A Pending JP2005516035A (ja) 2002-01-23 2003-01-21 I型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用

Country Status (14)

Country Link
US (2) US7045502B2 (cg-RX-API-DMAC7.html)
EP (1) EP1469874A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005516035A (cg-RX-API-DMAC7.html)
KR (1) KR20040075096A (cg-RX-API-DMAC7.html)
CN (1) CN100430089C (cg-RX-API-DMAC7.html)
BR (1) BR0306798A (cg-RX-API-DMAC7.html)
CA (1) CA2472241A1 (cg-RX-API-DMAC7.html)
IL (1) IL162853A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007192A (cg-RX-API-DMAC7.html)
NO (1) NO20043483L (cg-RX-API-DMAC7.html)
NZ (1) NZ533749A (cg-RX-API-DMAC7.html)
SE (1) SE0200198D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003061682A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405342B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
CN121843705A (zh) 2023-05-03 2026-04-10 萨那生物科技公司 工程化胰岛细胞的给药和施用方法
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Similar Documents

Publication Publication Date Title
JP2007519649A5 (cg-RX-API-DMAC7.html)
JP2004538303A5 (cg-RX-API-DMAC7.html)
JP2007506775A5 (cg-RX-API-DMAC7.html)
JP2006515587A5 (cg-RX-API-DMAC7.html)
JP2008510691A5 (cg-RX-API-DMAC7.html)
JP2006143737A5 (cg-RX-API-DMAC7.html)
JP2004534057A5 (cg-RX-API-DMAC7.html)
JP2009500423A5 (cg-RX-API-DMAC7.html)
TW200528097A (en) Novel thiazolidin-4-one derivatives
JP2005526696A5 (cg-RX-API-DMAC7.html)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
JPH08504201A (ja) 抗うつ作用を有する医薬組成物としての2‐アミノ‐6‐n‐プロピル‐アミノ‐4,5,6,7‐テトラヒドロベンゾチアゾールの使用
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
JP2008512408A5 (cg-RX-API-DMAC7.html)
CA2621404A1 (en) Novel heterobicyclic derivatives
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
JP2007507494A5 (cg-RX-API-DMAC7.html)
JP2006502187A5 (cg-RX-API-DMAC7.html)
JP2002519425A5 (cg-RX-API-DMAC7.html)
JP2022505989A5 (cg-RX-API-DMAC7.html)
JP2006510606A5 (cg-RX-API-DMAC7.html)
JP2006510658A5 (cg-RX-API-DMAC7.html)
JPWO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
JP2004525178A5 (cg-RX-API-DMAC7.html)